Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next

Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
weberfr8

/by
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
arcticnovartis

  • Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads
  • Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settings
/by
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis

  • First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults
     
  • Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option from ongoing dosing approaches
/by
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis

  • Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety concerns2

  • With global CIndU prevalence of 29 million3,4; greater than 50% of patients experience significant disease burden despite treatment with H1-antihistamines; no approved targeted therapies exist5,6
/by
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
arcticnovartis

  • Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation
  • New Phase IIIb REMIXED extension data in chronic spontaneous urticaria to provide additional efficacy and safety data for Rhapsido
  • Phase II Rhapsido food allergy dose-response analysis in adults with IgE-mediated peanut allergy also to be presented

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of A

/by
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
arcticnovartis

  • Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1

  • Vanrafia reduced protein in urine by 38.3% vs placebo at 9 months, with reductions sustained through end of treatment1,2

  • Patients additionally receiving background SGLT2 inhibitors also consistently showed slower kidney function decline with Vanrafia vs placebo1,2
/by
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
arcticnovartis

  • Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,2
  • Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease primarily affecting people over 50; extended steroid use associated with poor outcomes with limited advanced treatments3–7
/by
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis

  • Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1
  • Clinically relevant 15.2% higher MMR rate achieved with Scemblix vs. 2G TKIs1
/by
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis

  • New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session
  • New ianalumab interim results from Sjögren’s Phase III extension study up to week 108 and Phase II data in systemic lupus erythematosus will be presented
/by